Decreased neutralization of SARS-CoV-2 global variants by therapeutic anti-spike protein monoclonal antibodies
T. Tada, B. M. Dcosta, H. Zhou, A. Vaill, W. Kazmierski, N. R. Landau
This study evaluates the neutralization activity of two monoclonal antibodies against SARS-CoV-2 variants, finding reduced efficacy against B.1.351 and mink cluster 5 due to specific spike protein mutations.
bioRxiv · Feb 18, 2021 · PreprintImmunology